02 October 2018
The British biotech sector enjoyed a big third quarter for VC financing. With more than £460 million ($600 million) in VC cash flowing into the bank accounts of U.K. biotechs, the sector has now raised 30% more money from public and private sources than it managed in all of last year.
Trade group the UK BioIndustry Association (BIA) shared the data (PDF) in its quarterly update on the state of biotech financing in Britain. The BIA data show that British biotechs raised £732 million on public and private markets across June, July and August, bringing the total haul for the year up to £1.56 billion. Last year, the financing total topped out at £1.2 billion.
The VC figures compare favorably to recent history, too. Having raised £927 million in venture cash across the first eight months of 2018, British biotechs have already raised 80% more than in all of last year and 17% more than in 2015, the Immunocore-driven high point of U.K. VC funding. In a sign of how much U.K. biotech financing has changed in recent years, the amount of VC cash raised so far in 2018 is 30% more than the sector managed across 2012, 2013 and 2014, combined.
This strong performance is built on sizable investments in multiple companies. Whereas the figures for 2015 were propped up by Immunocore’s megaround, this year has seen a wider range of biotechs pull in sizable sums. Orchard Therapeutics’ £115 million series C leads the way, but rounds from companies such as Freeline and BenevolentAI aren’t too far behind.
Yet the figures also show how far the U.K. has to go. The BIA wants the U.K. to establish itself as a global biotech hub to rival the San Francisco Bay Area and Massachusetts. The U.K. has the scientific credentials to support a bid for a seat at the top table but, despite the progress of recent years, it is still some way behind the U.S. clusters on the financial front.
Over the first half of 2018, biopharmas based in Massachusetts raised (PDF) $2.7 billion (£2.1 billion) from VCs. With the caveat that methodological variations make comparing VC data from different sources inexact, that suggests biopharmas in the state raised as much in six months as their U.K. counterparts did across 2016, 2017 and the first eight months of 2018.
31 October 2018
30 October 2018
29 October 2018
26 October 2018
Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.
We believe that Russian excellence in multi-disciplinary scientific and technological innovation, in synergy with the wave of entrepreneurial and creative talent now being unleashed with the rise of the Russian Millennial generation, will, against the backdrop of macroeconomic stability afforded by Russia’s vast natural resources, combine to make the world a much better place for everyone
We believe that most Russian companies, ideas, concepts and brands are enormously undervalued, not just in terms of their potential on the Russian markets, but in terms of their global potential. Our task is to identify this potential and execute against it, to world class standards of efficiency and effectiveness
In order to identify and unlock the potential value in the companies we work with, we have developed a holistic methodology which goes all the way from goals and strategies to the minute, concrete detail of day-to-day management operations
We work rapidly to develop goals and strategy, but in parallel we look for quick wins to generate early success and focus the employees, customers and partners on the company’s new mission and values and to demonstrate the immediate, short-term value we bring
Our success is your success. Our reward is based primarily on the quantifiable value we bring to the assets we manage and grow
Our expertise covers a wide range of industry sectors, geographic regions and functional specialisms. One of our key competitive differentiators is our ability to apply learning, experience, innovation and best practice from one sector to another and one country to another
In a rapidly globalizing business, social and political environment we uncompromisingly seek out business models that are the best in the world as the starting point for our work. Only in this way can we help our customers realize their true potential in a way which is both significant and sustainable
Our leading directors have decades of collective experience in multiple industries with public market accountability in realizing global concepts and adapting these to the realities and opportunities specific to Russia